Bokf Na Raises Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Bokf Na increased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 248.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 28,186 shares of the specialty pharmaceutical company’s stock after purchasing an additional 20,093 shares during the period. Bokf Na owned 0.05% of Supernus Pharmaceuticals worth $754,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SUPN. Commonwealth Equity Services LLC increased its stake in Supernus Pharmaceuticals by 3.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock worth $273,000 after acquiring an additional 350 shares during the last quarter. Covestor Ltd increased its stake in Supernus Pharmaceuticals by 15.3% in the 1st quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 358 shares during the last quarter. QRG Capital Management Inc. increased its stake in Supernus Pharmaceuticals by 2.6% in the 4th quarter. QRG Capital Management Inc. now owns 15,489 shares of the specialty pharmaceutical company’s stock worth $448,000 after acquiring an additional 398 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in Supernus Pharmaceuticals by 2.2% in the 2nd quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock worth $741,000 after acquiring an additional 600 shares during the last quarter. Finally, Texas Permanent School Fund Corp increased its stake in Supernus Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 47,814 shares of the specialty pharmaceutical company’s stock worth $1,631,000 after acquiring an additional 619 shares during the last quarter.

Supernus Pharmaceuticals Trading Up 0.7 %

Shares of Supernus Pharmaceuticals stock opened at $31.11 on Monday. The firm has a market capitalization of $1.71 billion, a PE ratio of -107.28 and a beta of 0.88. The business’s 50-day moving average price is $31.69 and its 200-day moving average price is $30.40. Supernus Pharmaceuticals, Inc. has a 12 month low of $21.99 and a 12 month high of $35.44.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.39 by ($0.03). The firm had revenue of $168.30 million for the quarter, compared to the consensus estimate of $148.83 million. Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. Supernus Pharmaceuticals’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.02) earnings per share. As a group, analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Piper Sandler lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $41.00 to $36.00 in a research note on Wednesday, September 11th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.